Bernhardt G Zeiher

Director Zeiher purchases 5.0K TRDA shares at $5.86; stock down -61.6% from 52-week high amid -87.9% revenue decline

Bernhardt G Zeiher, as a director, purchased 5,000 shares of Entrada Therapeutics at $5.86 on 2026-05-20, establishing an initial position in the company. The purchase comes as TRDA faces significant operational headwinds: quarterly revenue has collapsed to $875,000.00 against a net loss of $-39,717,000.00, with annual revenue declining -87.9% year-over-year. The stock has suffered steep declines, trading at $6.31 currently—down -61.6% from its 52-week high of $16.45 and -51.7% over the past 30 days. Zeiher's cross-ticker track record shows 1 prior buy with an average 90-day return of +37.8%, though this isolated prior transaction provides limited predictive value for performance at this specific ticker. The purchase reflects director participation in a distressed biotech name with severe revenue deterioration and consistent unprofitability.

Director Zeiher buys 10,000 shares of AMLX at $3.70; stock down 46.2% from 52-week high amid -77.1% annual revenue decline and $-72.7M net loss.

Bernhardt G. Zeiher, as a director, initiated a 10,000-share position in Amylyx Pharmaceuticals at $3.70 on 2025-03-20, spending $37,005.00 in total value. This purchase occurs in a severely challenged operating environment: the company posted a net loss of $-72.7M in its most recent full fiscal year, latest quarterly revenue of only $416.0K, and an annual revenue decline of -77.1% year-over-year. The stock is currently trading at $3.78, still -46.2% from its 52-week high of $7.03, suggesting the market has already priced in substantial losses of confidence. The timing of this insider acquisition coincides with the stock trading near historically depressed levels within its 52-week range, though it has recovered +14.6% over the past 30 days. Without visibility into the director's broader portfolio strategy or prior transaction history at this ticker, the purchase represents a discrete open-market acquisition at a point when both the company's financial trajectory and the stock's valuation reflect severe operational distress.